Navigation Links
New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market
Date:10/3/2007

LONDON, October 3 /PRNewswire/ -- Every successful originator company will one day be involved in or competing with biosimilar products, making biosimilars development a critical part of the future of biotechnology, says a new Scrip Report.

The first generation of biopharmaceuticals manufactured using recombinant technologies was launched in the 1980s, and patents protecting them are now nearing expiration. As with small molecule drugs, the expiration of patents creates an opportunity for generic biologicals to enter the market. This means that competition from biosimilars is likely to be a challenge for every successful biopharmaceutical product.

'Biosimilars, Biogenerics and Follow-on Biologics', a 237-page report, provides an in-depth review of the various milestones that have led the biosimilars arena to where it is today, as well as strategic insight for companies in both camps: the firms that are investing their R&D efforts into developing new biosimilars, and the innovators that are looking for ways to counter this new challenge. And the challenge is a significant one: from sales of $30 million in 2006, the biosimilars market is expected to be worth $3.2 billion as soon as 2011.

The EU already has legislation in place for the approval of biosimilars and, according to the Report, is expected to lead the way in the evolution of the biosimilars sector, making up 45% of the world market. The situation in the US has been more hotly contested, but this crucial market is set to follow Europe's lead following the passing of landmark legislation by the US Senate Health Committee in June 2007. In the same month another significant milestone in the development of biosimilars was reached when the European medicines agency (EMEA) recommended three biosimilar versions of recombinant erythropoietin (EPO), a complex glycoprotein, for approval.

The Report describes how companies are currently targeting products that are off-patent in Europe: in particular human growth hormone (hGH), EPO and granulocyte colony-stimulating factor (G-CSF). However, it points out that there are many more potential targets for development in areas that have so far attracted fewer developers in Western markets.

In the Report 59 protein and 14 peptide therapeutics are discussed, all of which achieved high-volume global sales in 2006. Half of the protein products generated sales in excess of $500 million.

Biosimilars development also brings with it a range of scientific issues including the critical assessment of equivalence. Important analytical procedures available for this purpose include techniques with an established role in protein analysis, as well as emerging techniques like nuclear magnetic resonance spectroscopy and mass spectrometry.

The Report profiles 15 selected companies based in India, Europe, the US, Canada and Israel, which are poised for competition in the (regulated) biosimilars market. It also forecasts in detail the top five protein therapeutics categories open to biosimilar competition, worth over 50% of the total protein market in 2006.

Scrip Reports publishes an extensive range of pharmaceutical therapeutic market reports, detailed analyses of the pharmaceutical market for specific geographic areas, in-depth profiles of companies operating in the industry, financial and statistical analyses, directories and other strategic reports on the healthcare sector.

Visit http://www.scripreports.com for more information.

For further press details contact:

Jenefer Trevena

Managing Editor

Scrip Publishing

Tel: +44-(0)20-7017-6989

Email: jenefer.trevena@informa.com

To purchase Biosimilars, Biogenerics and Follow-on Biologics, contact:

Andrew Maitland

Sales Manager

Tel: +44-(0)20-7017-6859

Email: andrew.maitland@informa.com and quote code: JR20003P


'/>"/>
SOURCE Scrip Reports
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
2. Omniscript RT Kit
3. Suggested applications for reverse transcriptases
4. Properties of Reverse Transcriptases
5. Reverse transcriptases suitable for one-step RT-PCRb
6. Reverse transcriptases suitable for two-step RT-PCRd
7. C. therm. Polymerase for Reverse Transcription in Two-Step RT-PCR
8. Choice of reverse transcription primers
9. Transcriptor Reverse Transcriptase
10. Increase the Power and Sensitivity for Your cDNA Synthesis with the New Transcriptor Reverse Transcriptase
11. Use of Transcriptor Reverse Transcriptase in Microarray Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
(Date:12/2/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... clinical research is through industry-wide collaboration, standardization and a beautiful technology experience. All three ... which convened more than 100 clinical trial leaders from over 40 sponsor, CRO and ...
(Date:12/2/2016)... -- The immunohistochemistry (IHC) market is projected to ... 7.3% during the forecast period of 2016 to 2021 dominated by ... for the largest share of immunohistochemistry (IHC) market, by end user. ... , , ... spread across 225 pages, profiling 10 companies and supported with 181 ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is excited to announce the ... focused on developing preclinical ophthalmology assets through proof ... potent anti-inflammatory created by Portage Pharmaceuticals Limited and ... with ocular surface and anterior segment diseases. This ...
Breaking Biology Technology:
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):